These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30238379)

  • 1. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
    Baris HE; Anderson E; Sozeri B; Dedeoglu F
    Clin Rheumatol; 2018 Dec; 37(12):3263-3273. PubMed ID: 30238379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic onset juvenile idiopathic arthritis: a single center experience.
    Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
    Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).
    Hedrich CM; Bruck N; Fiebig B; Gahr M
    Rheumatol Int; 2012 Nov; 32(11):3525-30. PubMed ID: 22083619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.
    Janow G; Schanberg LE; Setoguchi S; Hasselblad V; Mellins ED; Schneider R; Kimura Y;
    J Rheumatol; 2016 Sep; 43(9):1755-62. PubMed ID: 27307527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
    Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
    Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
    Ong MS; Ringold S; Kimura Y; Schanberg LE; Tomlinson GA; Natter MD;
    Arthritis Rheumatol; 2021 Oct; 73(10):1910-1920. PubMed ID: 34105303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
    Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
    Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM
    Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.
    Barut K; Adrovic A; Sahin S; Tarcin G; Tahaoglu G; Koker O; Yildiz M; Kasapcopur O
    Int J Rheum Dis; 2019 Sep; 22(9):1661-1669. PubMed ID: 31273940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.
    Pardeo M; Pires Marafon D; Insalaco A; Bracaglia C; Nicolai R; Messia V; De Benedetti F
    J Rheumatol; 2015 Aug; 42(8):1523-7. PubMed ID: 26034148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
    Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis.
    Pedersen ML; Neve-Græsbøll A; Herlin T; Glerup M
    Pediatr Rheumatol Online J; 2023 Sep; 21(1):107. PubMed ID: 37742033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic-onset juvenile idiopathic arthritis: the changing life of a rare disease.
    Cimaz R; Von Scheven A; Hofer M
    Swiss Med Wkly; 2012; 142():w13582. PubMed ID: 22573189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis.
    Saccomanno B; Tibaldi J; Minoia F; Bagnasco F; Pistorio A; Guariento A; Caorsi R; Consolaro A; Gattorno M; Ravelli A
    J Rheumatol; 2019 Apr; 46(4):416-421. PubMed ID: 30647180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.
    Kearsley-Fleet L; Beresford MW; Davies R; De Cock D; Baildam E; Foster HE; Southwood TR; Thomson W; Hyrich KL
    Rheumatology (Oxford); 2019 Jan; 58(1):94-102. PubMed ID: 30137641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis.
    Huang B; Qiu T; Chen C; Zhang Y; Seid M; Lovell D; Brunner HI; Morgan EM;
    RMD Open; 2020 Jan; 6(1):. PubMed ID: 32396520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Self-Reported Pain in Juvenile Idiopathic Arthritis as Related to Long-Term Outcomes: Results From the Nordic Juvenile Idiopathic Arthritis Cohort Study.
    Arnstad ED; Rypdal V; Peltoniemi S; Herlin T; Berntson L; Fasth A; Nielsen S; Glerup M; Ekelund M; Zak M; Aalto K; Nordal E; Romundstad PR; Rygg M;
    Arthritis Care Res (Hoboken); 2019 Jul; 71(7):961-969. PubMed ID: 30055093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
    Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ
    Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotechnological therapeutic in Juvenile Idiopathic Arthritis: Pathophysiological implications and targeted therapies.
    Pinto AM; Ascenção I; Rodrigues M; Brito I
    ARP Rheumatol; 2023; 2(4):299-306. PubMed ID: 38174749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.